Vanguard Global Advisers
TGTX icon

Vanguard Global Advisers’s TG Therapeutics TGTX Stock Holding History

Vanguard Global Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Sell
50,802
-4,702
-8% -$192K ﹤0.01% 1055
2026
Q1 		$1.84M Buy
+55,504
New +$1.65M ﹤0.01% 1247

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Vanguard Global Advisers's TGTX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its TG Therapeutics (TGTX) stake by 8.5% in Q2 2026, selling an estimated $192K and leaving 50,802 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1055.

Vanguard Global Advisers first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 424 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Vanguard Global Advisers held 50,802 shares of TG Therapeutics worth $2.79M as of Q2 2026.
  • Vanguard Global Advisers sold 4,702 TG Therapeutics shares in Q2 2026, an estimated $192K.
  • TG Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1055 holding.
  • Vanguard Global Advisers first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 424 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.